Browsing Tag
CRENESSITY
3 posts
Can CRENESSITY’s weight-loss benefit open doors for off-label interest in broader metabolic disorders?
Neurocrine Biosciences’ CRENESSITY shows weight-loss benefits in CAH—could this rare disease drug spark interest in obesity and insulin resistance care?
Neurocrine Biosciences’ one-year CAHtalyst phase 3 data shows sustained weight and insulin-resistance benefits in CAH patients
Neurocrine Biosciences’ CRENESSITY Phase 3 data shows strong weight and metabolic benefits in CAH—see what this means for NBIX stock and future sales.
FDA approves CRENESSITY: A breakthrough treatment from Neurocrine Biosciences for classic congenital adrenal hyperplasia
Neurocrine Biosciences has announced US Food and Drug Administration (FDA) approval of CRENESSITY, marking a significant milestone in…